PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393496
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393496
The Asia-pacific uterine cancer drugs market is expected to reach USD 958,896.20 million by 2030 from USD 550,332.54 million in 2022, growing at a CAGR of 7.7% during the forecast period of 2023 to 2030.
Asia-pacific Uterine Cancer Drugs Market, By Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generic and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, and rest of Asia-Pacific) - Industry Trends and Forecast to 2030.